Währungen / CLDX
CLDX: Celldex Therapeutics Inc
22.08
USD
0.30
(1.34%)
Der Wechselkurs von CLDX hat sich für heute um -1.34% verändert. Im Laufe des Tages wurde das Instrument von einem Tief von 21.71 bis zu einem Hoch von 23.02 gehandelt.
Verfolgen Sie die Celldex Therapeutics Inc-Dynamik. Mit Echtzeit-Kursen können Sie schnell auf Marktveränderungen reagieren. Indem Sie zwischen verschiedenen Zeitrahmen wechseln, können Sie Kurstrends und -dynamik nach Minuten, Stunden, Tagen, Wochen und Monaten verfolgen. Nutzen Sie diese Informationen, um Marktveränderungen vorherzusagen und fundierte Handelsentscheidungen zu treffen.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
CLDX News
- Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track (CLDX)
- Why Is Celldex Therapeutics Stock Falling Today - Celldex Therapeutics (NASDAQ:CLDX)
- La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Celldex Therapeutics (NASDAQ:CLDX), Alcon (NYSE:ALC)
- Stifel reiterates Buy rating on Celldex stock despite EoE setback
- H.C. Wainwright reiterates Buy rating on Eupraxia Pharmaceuticals stock
- Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Color Star Tech (NASDAQ:ADD), Aspen Insurance Hldgs (NYSE:AHL)
- Celldex stock price target lowered to $62 at Canaccord on EoE program halt
- Celldex stock price target lowered to $42 by H.C. Wainwright
- Celldex stock falls as Wells Fargo cuts price target on EOE trial failure
- Celldex’s mast cell therapy fails to improve eosinophilic esophagitis
- Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
- Celldex Therapeutics earnings beat by $0.01, revenue fell short of estimates
- scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
- Jasper Therapeutics stock holds Market Outperform rating at JMP despite setback
- Celldex stock price target maintained at $50 by H.C. Wainwright
- Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
- Crude Oil Rises 6%; US Consumer Sentiment Surges In June - Senmiao Tech (NASDAQ:AIHS), Chanson International (NASDAQ:CHSN)
- Celldex shares jump on impressive skin disorder drug data
- Visa, Mastercard lead Friday’s market cap stock movers
- Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - Bunge Global (NYSE:BG), AleAnna (NASDAQ:ANNA)
- Celldex stock maintains Overweight rating on promising CSU therapy results
- Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
- Celldex stock rating reiterated at Buy by Canaccord ahead of data release
- Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
Tagesspanne
21.71
23.02
Jahresspanne
14.40
46.90
- Vorheriger Schlusskurs
- 22.38
- Eröffnung
- 22.52
- Bid
- 22.08
- Ask
- 22.38
- Tief
- 21.71
- Hoch
- 23.02
- Volumen
- 2.143 K
- Tagesänderung
- -1.34%
- Monatsänderung
- 1.24%
- 6-Monatsänderung
- 3.81%
- Jahresänderung
- -45.82%
30 August, Samstag